

**LASTACAFT - alcaftadine solution/ drops**  
**Physicians Total Care, Inc.**

-----

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use LASTACAFT™ safely and effectively. See full prescribing information for LASTACAFT™.

**LASTACAFT™ (alcaftadine ophthalmic solution) 0.25%**

**Initial U.S. Approval: 2010**

----- **INDICATIONS AND USAGE** -----

LASTACAFT™ is an H<sub>1</sub> histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. (1)

----- **DOSAGE AND ADMINISTRATION** -----

Instill one drop in each eye once daily. (2)

----- **DOSAGE FORMS AND STRENGTHS** -----

Ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL) (3)

----- **WARNINGS AND PRECAUTIONS** -----

- To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. (5.1)
- **LASTACAFT™** should not be used to treat contact lens-related irritation. (5.2)
- Remove contact lenses prior to instillation of **LASTACAFT™**. (5.2)

----- **ADVERSE REACTIONS** -----

The most common ocular adverse reactions, occurring in < 4% of **LASTACAFT™**-treated eyes, were eye irritation, burning and/or stinging on instillation, eye redness, and eye pruritus. (6.1)

The most common non-ocular adverse reactions, occurring in < 3% of subjects with **LASTACAFT™**-treated eyes, were nasopharyngitis, headache and influenza. (6.2)

**To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 8/2011**

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

**2 DOSAGE AND ADMINISTRATION**

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

5.1 Contamination of Tip and Solution

5.2 Contact Lens Use

5.3 Topical Ophthalmic Use Only

**6 ADVERSE REACTIONS**

6.1 Ocular Adverse Reactions

6.2 Non-ocular Adverse Reactions

**8 USE IN SPECIFIC POPULATIONS**

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.3 Pharmacokinetics

### **13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### **14 CLINICAL STUDIES**

### **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **17 PATIENT COUNSELING INFORMATION**

17.1 Sterility of Dropper Tip

17.2 Concomitant Use of Contact Lenses

17.3 Topical Ophthalmic Use only

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

**LASTACAFT™** is an H<sub>1</sub> histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

### **2 DOSAGE AND ADMINISTRATION**

Instill one drop in each eye once daily.

### **3 DOSAGE FORMS AND STRENGTHS**

Topical ophthalmic solution containing alcaftadine, 0.25% (2.5 mg/mL).

### **4 CONTRAINDICATIONS**

None.

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Contamination of Tip and Solution**

To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

#### **5.2 Contact Lens Use**

Patients should be advised not to wear a contact lens if their eye is red. **LASTACAFT™** should not be used to treat contact lens-related irritation.

**LASTACAFT™** should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of **LASTACAFT™**. The preservative in **LASTACAFT™**, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of **LASTACAFT™**.

#### **5.3 Topical Ophthalmic Use Only**

**LASTACAFT™** is for topical ophthalmic use only.

## 6 ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

### 6.1 Ocular Adverse Reactions

The most frequent ocular adverse reactions, occurring in < 4% of **LASTACAFT™**-treated eyes, were eye irritation, burning and/or stinging upon instillation, eye redness and eye pruritus.

### 6.2 Non-ocular Adverse Reactions

The most frequent non-ocular adverse reactions, occurring in < 3% of subjects with **LASTACAFT™**-treated eyes, were nasopharyngitis, headache and influenza. Some of these events were similar to the underlying disease being studied.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

Pregnancy Category B. Reproduction studies performed in rats and rabbits revealed no evidence of impaired female reproduction or harm to the fetus due to alcaftadine. Oral doses in rats and rabbits of 20 and 80 mg/kg/day, respectively, produced plasma exposure levels approximately 200 and 9000 times the plasma exposure at the recommended human ocular dose. There are however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

### 8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when **LASTACAFT™** is administered to a nursing woman.

### 8.4 Pediatric Use

Safety and effectiveness in pediatric patients below the age of 2 years have not been established.

### 8.5 Geriatric Use

No overall differences in safety or effectiveness were observed between elderly and younger subjects.

## 11 DESCRIPTION

**LASTACAFT™** is a sterile, topically administered H<sub>1</sub> receptor antagonist containing alcaftadine for ophthalmic use.


Alcaftadine is a white to yellow powder with an empirical formula of C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O and a molecular weight of 307.39.

**Contains: Active:** alcaftadine 0.25% (2.5 mg/mL). **Preservative:** benzalkonium chloride 0.005%.

**Inactives:** edetate disodium, monobasic sodium phosphate, purified water, sodium chloride, sodium hydroxide and/or hydrochloric acid to adjust pH

**Chemical Name:** 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3] benzazepine-3-carboxaldehyde

**Structural Formula:**



The drug product has a pH of approximately 7 and an osmolality of approximately 290 mOsm/kg.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Alcaftadine is a H<sub>1</sub> histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.

### 12.3 Pharmacokinetics

#### *Absorption*

Following bilateral topical ocular administration of alcaftadine ophthalmic solution, 0.25%, the mean plasma C<sub>max</sub> of alcaftadine was approximately 60 pg/mL and the median T<sub>max</sub> occurred at 15 minutes. Plasma concentrations of alcaftadine were below the lower limit of quantification (10 pg/mL) by 3 hours after dosing. The mean C<sub>max</sub> of the active carboxylic acid metabolite was approximately 3 ng/mL and occurred at 1 hour after dosing. Plasma concentrations of the carboxylic acid metabolite were below the lower limit of quantification (100 pg/mL) by 12 hours after dosing. There was no indication of systemic accumulation or changes in plasma exposure of alcaftadine or the active metabolite following daily topical ocular administration.

#### *Distribution*

The protein binding of alcaftadine and the active metabolite are 39.2% and 62.7%, respectively.

#### *Metabolism*

The metabolism of alcaftadine is mediated by non-CYP450 cytosolic enzymes to the active carboxylic acid metabolite.

#### *Excretion*

The elimination half-life of the carboxylic acid metabolite is approximately 2 hours following topical ocular administration. Based on data following oral administration of alcaftadine, the carboxylic acid metabolite is primarily eliminated unchanged in the urine.

In vitro studies showed that neither alcaftadine nor the carboxylic acid metabolite substantially inhibited reactions catalyzed by major CYP450 enzymes.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Alcaftadine was not mutagenic or genotoxic in the Ames test, the mouse lymphoma assay or the mouse

micronucleus assay.

Alcaftadine was found to have no effect on fertility of male and female rats at oral doses up to 20 mg/kg/day (approximately 200 times the plasma exposure at the recommended human ocular dose).

## **14 CLINICAL STUDIES**

Clinical efficacy was evaluated in conjunctival allergen challenge (CAC) studies. **LASTACAFT™** was more effective than its vehicle in preventing ocular itching in patients with allergic conjunctivitis induced by an ocular allergen challenge, both at 3 minutes post-dosing and at 16 hours post-dosing of **LASTACAFT™**.

The safety of **LASTACAFT™** was evaluated in a randomized clinical study of 909 subjects over a period of 6 weeks.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

**LASTACAFT™** (alcaftadine ophthalmic solution) 0.25% is supplied in an opaque, white low-density polyethylene bottle with a white polypropylene cap.

3 mL fill in 5 mL bottle    NDC 54868-6294-0

**Storage:** Store at 15-25°C (59-77°F).

## **17 PATIENT COUNSELING INFORMATION**

### **17.1 Sterility of Dropper Tip**

Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.

### **17.2 Concomitant Use of Contact Lenses**

Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that **LASTACAFT™** should not be used to treat contact lens-related irritation. Patients should also be advised to remove contact lenses prior to instillation of **LASTACAFT™**. The preservative in **LASTACAFT™**, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of **LASTACAFT™**.

### **17.3 Topical Ophthalmic Use only**

For topical ophthalmic administration only.

### **ALLERGAN**

Manufactured for Allergan, Inc., Irvine, CA 92612, U.S.A.

© 2010 Allergan, Inc.

® and ™ marks owned by Allergan, Inc.

Manufactured in the U.S.A. by JHP Pharmaceuticals, LLC

72409US10B

### **Relabeling and Repackaging by:**

Physicians Total Care, Inc., Tulsa, OK 74146

**NDC 54868-6294-0**

DIST. BY: PHYSICIANS TOTAL CARE

TULSA, OK 74146

NDC 54868-6294-0 3 ML

LASTACFT 0.25% SOL

LOT # 0000 EXP. DATE 01/60

MFG. BY: JAF PHARMACEUTICALS, LLC  
ROCHESTER, MI 48307



62940030000

## LASTACFT™

(alcaftadine ophthalmic

solution) 0.25%

3 mL Sterile

## LASTACFT

alcaftadine solution/ drops

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:54868-6294(NDC:0023-4290)
Route of Administration	OPHTHALMIC		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
alcaftadine (UNII: 7Z8O94ECSX) (alcaftadine - UNII:7Z8O94ECSX)	alcaftadine	2.5 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
benzalkonium chloride (UNII: F5UM2KM3W7)	
edetate disodium (UNII: 7FLD91C86K)	
sodium phosphate, monobasic (UNII: 3980JH2SW)	
water (UNII: 059QF0KO0R)	
sodium chloride (UNII: 451W47IQ8X)	
sodium hydroxide (UNII: 55X04QC32I)	
hydrochloric acid (UNII: QTT17582CB)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:54868-6294-0	1 in 1 CARTON		
1		3 mL in 1 BOTTLE, PLASTIC		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA022134	08/19/2011	

**Labeler** - Physicians Total Care, Inc. (194123980)

## Establishment

Name	Address	ID/FEI	Business Operations
Physicians Total Care, Inc.		194123980	relabel, repack

Revised: 9/2010

Physicians Total Care, Inc.